BSE - Delayed Quote INR

Kilitch Drugs (India) Limited (KILITCH.BO)

Compare
337.00
-7.55
(-2.19%)
At close: 3:27:48 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Mr. Mukund Prataprai Mehta B.Com., LL.B. Executive Chairman & MD 6M -- 1953
Ms. Mira Bhavin Mehta Managing Director 2.4M -- 1978
Mr. Bhavin Mukund Mehta B.Pharm. Whole-time Director 8.4M -- 1976
Mr. Sunil Sureshji Jain Chief Financial Officer 1.5M -- 1983
Tajouddin Ansari VP-Marketing & Operation -- -- --
Rajesh Khatri General Manager - Administration -- -- 1975
Ms. Pushpa Nyoupane Company Secretary & Compliance Officer -- -- --

Kilitch Drugs (India) Limited

37/39, Ujagar Industrial Estate
Waman Tukaram Patil Marg Deonar
Mumbai, 400088
India
91 22 6121 4100 https://www.kilitch.com
Sector: 
Healthcare
Full Time Employees: 
168

Description

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Corporate Governance

Kilitch Drugs (India) Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 6, 2025 at 10:59 AM UTC - February 10, 2025 at 12:00 PM UTC

Kilitch Drugs (India) Limited Earnings Date

Recent Events

September 20, 2019 at 12:00 AM UTC

Ex-Dividend Date